摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 4-(7-oxo-8H-1,8-naphthyridin-4-yl)piperazine-1-carboxylate | 250264-30-3

中文名称
——
中文别名
——
英文名称
ethyl 4-(7-oxo-8H-1,8-naphthyridin-4-yl)piperazine-1-carboxylate
英文别名
——
ethyl 4-(7-oxo-8H-1,8-naphthyridin-4-yl)piperazine-1-carboxylate化学式
CAS
250264-30-3
化学式
C15H18N4O3
mdl
——
分子量
302.333
InChiKey
VDFLKMBCLOTEGN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    22
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    74.8
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    ethyl 4-(7-oxo-8H-1,8-naphthyridin-4-yl)piperazine-1-carboxylatesodium hydroxide 、 sodium hydride 作用下, 以 乙醇N,N-二甲基甲酰胺 为溶剂, 反应 16.0h, 生成 1-Methyl-5-piperazin-1-yl-1H-[1,8]naphthyridin-2-one
    参考文献:
    名称:
    Synthesis of 1,8-naphthyridine derivatives: potential antihypertensive agents – Part VIII
    摘要:
    A series of (ethoxycarbonylpiperazinyl)- and piperazinyl-1,8-naphthyridine derivatives, variously substituted, has been synthesized and pharmacologically investigated for anthihypertensive activity. Some of them exhibited a significant and prolonged decrease of the mean arterial pressure (MAP) on spontaneously hypertensive rats. On the basis of the pharmacological results, no structure-activity relationship can be deduced at this time. Moreover, the most active compound 4e, was investigated by means of in vitro pharmacological functional studies and in vivo, as a diuretic agent, to determine a possible mechanism of the antihypertensive activity, which results in a probably non-competitive antagonism against alpha(1), vascular adrenoceptors. This mechanism was also shown by the compounds 8 and 13. (C) Elsevier, Paris.
    DOI:
    10.1016/s0223-5234(99)80099-3
  • 作为产物:
    描述:
    参考文献:
    名称:
    Synthesis of 1,8-naphthyridine derivatives: potential antihypertensive agents – Part VIII
    摘要:
    A series of (ethoxycarbonylpiperazinyl)- and piperazinyl-1,8-naphthyridine derivatives, variously substituted, has been synthesized and pharmacologically investigated for anthihypertensive activity. Some of them exhibited a significant and prolonged decrease of the mean arterial pressure (MAP) on spontaneously hypertensive rats. On the basis of the pharmacological results, no structure-activity relationship can be deduced at this time. Moreover, the most active compound 4e, was investigated by means of in vitro pharmacological functional studies and in vivo, as a diuretic agent, to determine a possible mechanism of the antihypertensive activity, which results in a probably non-competitive antagonism against alpha(1), vascular adrenoceptors. This mechanism was also shown by the compounds 8 and 13. (C) Elsevier, Paris.
    DOI:
    10.1016/s0223-5234(99)80099-3
点击查看最新优质反应信息

文献信息

  • Synthesis of 1,8-naphthyridine derivatives: potential antihypertensive agents – Part VIII
    作者:Pier Luigi Ferrarini、Claudio Mori、Vincenzo Calderone、Lorella Calzolari、Paola Nieri、Giuseppe Saccomanni、Enrica Martinotti
    DOI:10.1016/s0223-5234(99)80099-3
    日期:1999.6
    A series of (ethoxycarbonylpiperazinyl)- and piperazinyl-1,8-naphthyridine derivatives, variously substituted, has been synthesized and pharmacologically investigated for anthihypertensive activity. Some of them exhibited a significant and prolonged decrease of the mean arterial pressure (MAP) on spontaneously hypertensive rats. On the basis of the pharmacological results, no structure-activity relationship can be deduced at this time. Moreover, the most active compound 4e, was investigated by means of in vitro pharmacological functional studies and in vivo, as a diuretic agent, to determine a possible mechanism of the antihypertensive activity, which results in a probably non-competitive antagonism against alpha(1), vascular adrenoceptors. This mechanism was also shown by the compounds 8 and 13. (C) Elsevier, Paris.
查看更多